EP3356353A1 — Inhibitors of kras g12c mutant proteins
Assigned to Araxes Pharma LLC · Expires 2018-08-08 · 8y expired
What this patent protects
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein Z, Y R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , G 3 , G 4 ,…
USPTO Abstract
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein Z, Y R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , G 3 , G 4 , L 1 , m 1 , m 2 , m 3 , m 4 , n and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.